title: Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
abstract: Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.
authors.affiliation: Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. tahara@ims.u-tokyo.ac.jp
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tahara
authors.forename: Marimo
authors.initials: M
authors.lastname: Sato
authors.forename: Magdalena
authors.initials: M
authors.lastname: Thurin
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: Lisa H
authors.initials: LH
authors.lastname: Butterfield
authors.forename: Mary L
authors.initials: ML
authors.lastname: Disis
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fox
authors.forename: Peter P
authors.initials: PP
authors.lastname: Lee
authors.forename: Samir N
authors.initials: SN
authors.lastname: Khleif
authors.forename: Jon M
authors.initials: JM
authors.lastname: Wigginton
authors.forename: Stefan
authors.initials: S
authors.lastname: Ambs
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Akutsu
authors.forename: Damien
authors.initials: D
authors.lastname: Chaussabel
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Oleg
authors.initials: O
authors.lastname: Eremin
authors.forename: Wolf Hervé
authors.initials: WH
authors.lastname: Fridman
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hirohashi
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
authors.forename: James
authors.initials: J
authors.lastname: Jacobson
authors.forename: Masahisa
authors.initials: M
authors.lastname: Jinushi
authors.forename: Akira
authors.initials: A
authors.lastname: Kanamoto
authors.forename: Mohammed
authors.initials: M
authors.lastname: Kashani-Sabet
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kato
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kawakami
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: Thomas O
authors.initials: TO
authors.lastname: Kleen
authors.forename: Paul V
authors.initials: PV
authors.lastname: Lehmann
authors.forename: Lance
authors.initials: L
authors.lastname: Liotta
authors.forename: Michael T
authors.initials: MT
authors.lastname: Lotze
authors.forename: Michele
authors.initials: M
authors.lastname: Maio
authors.forename: Anatoli
authors.initials: A
authors.lastname: Malyguine
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Masucci
authors.forename: Hisahiro
authors.initials: H
authors.lastname: Matsubara
authors.forename: Shawmarie
authors.initials: S
authors.lastname: Mayrand-Chung
authors.forename: Kiminori
authors.initials: K
authors.lastname: Nakamura
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Nishikawa
authors.forename: A Karolina
authors.initials: AK
authors.lastname: Palucka
authors.forename: Emanuel F
authors.initials: EF
authors.lastname: Petricoin
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Pos
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.forename: Licia
authors.initials: L
authors.lastname: Rivoltini
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
authors.forename: Craig L
authors.initials: CL
authors.lastname: Slingluff
authors.forename: Howard
authors.initials: H
authors.lastname: Streicher
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: Hiroya
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Minoru
authors.initials: M
authors.lastname: Toyota
authors.forename: Hisashi
authors.initials: H
authors.lastname: Wada
authors.forename: Xifeng
authors.initials: X
authors.lastname: Wu
authors.forename: Julia
authors.initials: J
authors.lastname: Wulfkuhle
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yaguchi
authors.forename: Benjamin
authors.initials: B
authors.lastname: Zeskind
authors.forename: Yingdong
authors.initials: Y
authors.lastname: Zhao
authors.forename: Mai-Britt
authors.initials: MB
authors.lastname: Zocca
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D014408:Biomarkers, Tumor / Q000276:immunology*; D035843:Biomedical Research / Q000639:trends*; D006801:Humans; D007564:Japan; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000188:drug therapy*; D015203:Reproducibility of Results; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D014408:Biomarkers, Tumor